A Randomized Phase II Study Comparing Nivolumab with Carboplatin–Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)

PURPOSE: Although the efficacy of programmed cell death–1 (PD-1) blockade is generally poor for non–small cell lung cancer (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) gene, EGFR tyrosine kinase inhibitors (TKIs) may improve the tumor immune microenvironment. We p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayashi, Hidetoshi, Sugawara, Shunichi, Fukuda, Yasushi, Fujimoto, Daichi, Miura, Satoru, Ota, Keiichi, Ozawa, Yuichi, Hara, Satoshi, Tanizaki, Junko, Azuma, Koichi, Omori, Shota, Tachihara, Motoko, Nishino, Kazumi, Bessho, Akihiro, Chiba, Yasutaka, Haratani, Koji, Sakai, Kazuko, Nishio, Kazuto, Yamamoto, Nobuyuki, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397372/
https://www.ncbi.nlm.nih.gov/pubmed/34921023
http://dx.doi.org/10.1158/1078-0432.CCR-21-3194

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397372/
https://www.ncbi.nlm.nih.gov/pubmed/34921023
http://dx.doi.org/10.1158/1078-0432.CCR-21-3194

Ejemplares similares